Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Multiple Myeloma × CT103A chimeric antigen receptor × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 113 Lenalidomide 52 Bortezomib 48 Melphalan 40 Calcium Dobesilate 39 Cyclophosphamide 34 pomalidomide 30 carfilzomib 30 daratumumab 19 belantamab mafodotin 19 Peripheral Blood Stem Cell Transplantation 17 ixazomib 14 fludarabine 12 dexamethasone acetate 12 Filgrastim 12 Bendamustine Hydrochloride 12 fludarabine phosphate 11 Tacrolimus 11 dexamethasone 21-phosphate 10 auricularum 10 Whole-Body Irradiation 10 Prednisone 10 selinexor 9 liposomal doxorubicin 8 iberdomide 8 Mycophenolic Acid 8 Cyclosporine 8 venetoclax 7 pembrolizumab 7 Sirolimus 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05066646 2021-11-23

FUMANBA-1

Nanjing IASO Biotechnology Co., Ltd.

Phase 1/2 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡